The short answer
MT-2, or Melanotan II, is a cyclic seven-residue peptide analogue of alpha-melanocyte-stimulating hormone at 1024.2 Da. It is unlicensed in every jurisdiction, and it should not be confused with Melanotan I (afamelanotide) which is a different molecule and an approved medicine.
Key facts
- Molecular weight
- 1024.2 Da
- Formula
- C50H69N15O9
- PubChem CID
- 92432
- CAS
- 121062-08-6
- Residues
- Seven, cyclic (2-7)
- Parent hormone
- alpha-MSH, 1,664.9 Da
- Melanotan I
- Afamelanotide (different, and approved)
- MT-2 authorisation
- None, anywhere
What it is
The MT2 peptide is a cyclic heptapeptide built as an analogue of alpha-melanocyte-stimulating hormone, written Melanotan II or MT-II in the research literature. Where the parent hormone is thirteen linear residues at 1,664.9 Da, MT-2 compresses the receptor-binding portion into seven residues closed into a ring, at 1024.2 Da.
The confusion that must be cleared first
Melanotan I and Melanotan II are not variants of one product. Melanotan I is afamelanotide, a linear thirteen-residue peptide at 1,646.8 Da, marketed as Scenesse and approved for erythropoietic protoporphyria. Melanotan II is this compound: cyclic, seven residues, 622 Da lighter, and authorised nowhere. Searching a database for melanotan returns the approved one.
Research material referenced
MT-2 10mg, third-party HPLC tested
How it relates to KPV
Both derive from alpha-MSH and take opposite halves of it. KPV is the C-terminal tripeptide carrying the anti-inflammatory activity, built specifically to leave the pigmentation behind. MT-2 is built around the melanocortin-receptor-binding core, which is the portion KPV discards. Same parent hormone, opposite design intentions.
Why it is cyclic
A lactam bridge closes the ring between positions 2 and 7. Cyclisation locks conformation, which both improves receptor engagement and removes the free ends that exopeptidases attack. It is one of four separate protease-resistance features built into this molecule.
The safety literature
There is one, and it is not incidental. Reid and colleagues reported atypical melanocytic naevi following melanotan injection in the Irish Medical Journal in 2013. Eijmael and colleagues published on the risks of tanning with this class in the Nederlands Tijdschrift voor Geneeskunde in 2022. Dermatological case reports of an unlicensed injectable compound are the kind of information that should be stated rather than omitted.
Regulatory position
MT-2 holds no marketing authorisation from the MHRA, EMA, FDA or any other regulator. It is supplied here for laboratory research only, and no claim is made about pigmentation, appearance, or any effect in any person.
Frequently asked questions
Is MT-2 the same as Melanotan I?
No. Melanotan I is afamelanotide, a linear 13-residue peptide at 1,646.8 Da and an approved medicine. MT-2 is a cyclic 7-residue peptide at 1024.2 Da, approved nowhere.
How does it relate to KPV?
Both come from alpha-MSH. KPV takes the anti-inflammatory C-terminus; MT-2 is built around the receptor-binding core KPV leaves behind.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubChemPubChem · Melanotan II (CID 92432)pubchem.ncbi.nlm.nih.gov
- PubMedReid C et al., Atypical melanocytic naevi following melanotan injection. Ir Med J 2013 (PMID 23914578)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Afamelanotide (CID 16197727)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · alpha-MSH (CID 16133793)pubchem.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More MT-2 (Melanotan II) articles
- Two Compounds, One Parent, Opposite IntentionsAlpha-MSH does two unrelated things. KPV takes the anti-inflammatory C-terminus; MT-2 takes the receptor-binding core. Each discards what the other kept.
- Is Melanotan 2 Safe? What Has Actually Been PublishedCase reports of atypical melanocytic naevi following injection, and a 2022 review of the risks. What the dermatology literature has documented.
- Melanotan 2 Storage, Mixing and StabilityCyclisation, a D-amino acid and two capped termini make this among the most chemically stable peptides in the catalogue.
- Does Melanotan 2 Work Without UV?The receptor mechanism does not require UV, and the approved analogue proves pigmentation can rise without it. What that does and does not establish for MT-2.
- Melanotan 2 Onset: What Can and Cannot Be SaidNo controlled trial has measured a time course for MT-2. What melanin biology sets as a floor, and what the licensed analogue's data actually shows.